Guardant Health (NASDAQ:GH) offers non-invasive cancer diagnosis tests and is based out of the U.S. We step back from these recent swings to review Guardant Health’s performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?, reviews the near term reasons and the big picture. The context for the last few years:A closer look At Guardant Health’s Total Revenues over the last few years and the outlook. (Increase is on account of higher volumes of Guardant360 Oncology Test)This compares with Total Revenues growth of 97.4% in 2017.

Source: Forbes December 04, 2019 17:26 UTC